# One Health Group to raise gross proceeds of £8.0 million, admission to AIM

- Link: https://www.directorstalkinterviews.com/one-health-group-to-raise-gross-proceeds-of-8-0-million-admission-to-aim/4121186833
- Published: 2025-02-19T07:53:12+00:00
- Author: Amilia Stone

**[One Health Group plc](https://www.directorstalkinterviews.com/company/one-health-group-plc/ohgr.l)**(
AQSE:OHGR), a provider of NHS-funded medical procedures, is pleased to announce 
a conditional placing to raise minimum gross proceeds of £7.0 million, an open offer
to Qualifying Shareholders to raise up to £0.5 million and a retail offer to raise
up to £0.5 million.

The Placing to raise minimum gross proceeds of £7.0 million consists of:

· an issue of new Ordinary Shares to raise minimum gross proceeds of £5.2 million
for the Company; and

· the sale of existing Ordinary Shares held by certain Directors of the Company 
and the EBT Trustee to raise minimum gross proceeds of £1.8 million at a price of
180 pence per Placing Share.

The Capital Raising is conditional upon, inter alia, admission of the Enlarged Share
Capital to trading on AIM, cancellation of trading on the AQSE Growth Market and
the passing of the Resolutions at the General Meeting.

The net proceeds received by the Company will be used primarily to fund (alongside
existing cash) the Group’s first owned surgical hub through to operation. The surgical
hub, which is expected to cost between £8 million and £9 million, is expected to
be operational within one year of construction starting and deliver between £6 million
to £9 million of revenue per annum and is anticipated to be earnings enhancing in
its first full year of operation.

In order to provide Qualifying Shareholders who have not taken part in the Placing
with an opportunity to participate in the Capital Raising, the Company is providing
Qualifying Shareholders with a conditional invitation to subscribe, at the Issue
Price, for an aggregate of up to 277,634 new Ordinary Shares, to raise additional
gross proceeds of up to a maximum of approximately £0.5 million (before expenses).

In addition, the Company intends to launch an offering to both new and existing 
retail shareholders in the United Kingdom of up to 277,777 new Ordinary Shares via
the Retail Offer at the Issue Price through the Winterflood Retail Access Platform
to raise up to a further £0.5 million (before expenses). A further announcement 
will be made by the Company shortly regarding the Retail Offer and its terms. It
is expected that the Retail Offer will launch today, 19 February, shortly after 
this Announcement and will be open for applications up to 16:30 p.m. on 24 February
2025, or such later time and date as the Company, Panmure Liberum and Winterflood
Securities Limited may agree.

The Placing is being conducted through an accelerated bookbuild process (the “Bookbuild”),
which will be launched immediately following the release of this Announcement, in
accordance with the terms and condition set out in appendix 2 of this announcement.
Panmure Liberum Limited (“Panmure Liberum”) is acting as sole bookrunner in connection
with the Placing. The Placing is conditional on, inter alia, the passing of the 
Resolutions at the General Meeting, Cancellation and Admission. No part of the Capital
Raising is being underwritten.

**Capital Raising highlights**

**Placing:**

· The proposed Placing, by way of the Bookbuild, to raise a minimum of approximately
£7.0 million (before expenses) in aggregate at the Issue Price comprising:

i) a minimum of £5.2 million (before expenses) from the proposed placing of the 
New Placing Shares the net proceeds of which are to be used to fund, alongside existing
cash resources, the construction and delivery of One Health’s first owned surgical
hub through to operation; and

ii) a minimum of £1.2 million (before expenses) from the proposed sale of Existing
Ordinary Shares held by the Company’s EBT Trustee (with the net proceeds of the 
sale to be received by the EBT of which):

o approximately £750,000 will be used to repay an intercompany loan to the Company,
and

o the balance from the EBT Trustee sell down will remain in the EBT for the benefit
of employees of the Company; and

iii) a minimum of £0.6 million (before expenses) from the conditional sale of Ordinary
Shares by Derek Bickerstaff (Non-Executive Chairman) who currently holds an interest
of 56.9 per cent. of the Existing Ordinary Shares and Shantanu Shahane (Chief Medical
Officer) and his spouse, Angela Shahane, who in aggregate currently hold a direct
or indirect interest of approximately 3.3 per cent of the Existing Ordinary Shares
to facilitate additional liquidity in the Ordinary Shares and reduce controlling
shareholder interest to below 50 per cent. of the Enlarged Issued Share Capital.

· It is expected that, following its first full year of operations, the Group’s 
planned surgical hub will generate approximately £6 million to £9 million of revenue
per annum and be earnings enhancing.

· The first surgical hub is targeted to be operational in approximately 12 months
following commencement of development.

· Planning permission for the surgical hub is expected to be submitted shortly.

**Open Offer:**

· The Company is proposing to raise up to approximately £0.5 million (before expenses)
by way of the Open Offer at the Issue Price.

· The Open Offer will be made to Qualifying Shareholders pursuant to the terms and
conditions to be set out in the Circular.

· Subject to successful closing of the Bookbuild, the Open Offer will provide for
Qualifying Shareholders to subscribe for up to 277,634 Open Offer Shares at the 
Issue Price on the basis of:

1 Open Offer for every 38 Existing Ordinary Shares

    ```wp-block-code
            held by Qualifying Shareholders on the Record Date.
    ```

· Shareholders subscribing for their full entitlement under the Open Offer may request
additional Open Offer Shares through the Excess Application Facility.

**Retail Offer:**

· Proposed Retail Offer of up to 277,777 Retail Offer Shares to existing and new
qualifying UK retail investors to raise up to a further £0.5 million (before expenses)
at the Issue Price.

The net proceeds of the Open Offer and the Retail Offer will be used to support 
the Company’s general working capital and provide additional optionality for future
growth plans and surgical hubs.

The Issue Price represents a discount of approximately 14.3 per cent. to the closing
mid-market price of 210 pence per Existing Ordinary Share on 18 February 2025, being
the latest practicable date prior to the publication of this Announcement.

**Proposed Admission to AIM and Cancellation to trading on AQSE Growth Market**

In addition to the Capital Raising, the Company announces that its intention to 
cancel the admission of the Existing Ordinary Shares to trading on the AQSE Growth
Market (“Cancellation”) and to apply for admission of the New Ordinary Shares and
the Existing Ordinary Shares to trading on AIM (“Admission”). The Cancellation and
Admission are both conditional on completion of the Placing and the Open Offer and
the passing of the Resolutions at the General Meeting. Application will be made 
in due course to the London Stock Exchange for the New Ordinary Shares and the Existing
Ordinary Shares to be admitted to trading on AIM. Admission is expected to become
effective, and dealings in the Enlarged Issued Share Capital is expected to commence
at 8.00 a.m. on 20 March 2025 under the same TIDM and ISIN of “OHGR” and GB00BNNT0595
respectively. Cancellation of the trading of the Existing Ordinary Shares on the
AQSE Growth Market will take place simultaneously with Admission.

The Board considers Admission to be in the best interests of the Company and its
Shareholders given the growing scale of the business. The Board believe AIM is a
more appropriate market for the Company and will enable it to attract a wider pool
of investors, provide greater access to capital for growth and, over time, improve
liquidity in the Ordinary Shares.

The Schedule One Announcement in connection with Admission has been published today,
and the Appendix, containing Company information that is not already in the public
domain, will be published on the Company’s website at https://www.onehealth.co.uk/
investors.

Panmure Liberum is acting as AQSE Corporate Adviser to the Company for the purposes
of the AQSE Exchange Rules and as Nominated Adviser to the Company for the purposes
of the AIM Rules for Companies in connection with Admission.

Posting of Circular

The Company intends to publish and send a circular (the “Circular”) to Shareholders
containing further details of the Capital Raising and the Notice of General Meeting
on or around 20 February 2025. The Circular will also be available on the Company’s
website: https://www.onehealth.co.uk/investors.

**General Meeting**

The Capital Raising is conditional upon, inter alia, the passing of the Resolutions
at the General Meeting. The Company will hold the General Meeting at 131 Psalter
Lane, Sheffield, South Yorkshire, S11 8UX at 10.00 a.m. on 10 March 2025.

If the conditions relating to the issue of the Placing Shares are not satisfied 
or the Placing Agreement is terminated in accordance with its terms, the Placing
shares will not be issued, and the Company will not receive any proceeds from the
Placing. If the Placing does not proceed, neither the Open Offer nor Retail Offer
will proceed, and neither the Cancellation nor Admission will occur. In such circumstances,
the Existing Ordinary Shares will continue to trade on the AQSE Growth Market.

The Expected Timetable of Principal Events is set out in appendix 3 of this Announcement.
This Announcement should be read in its entirety. In particular, you should read
and understand the information provided in the “Important Notices” section below
and the appendices to this Announcement (which form part of this Announcement) which
includes the terms and conditions of the Fundraising.

Share on:
